MacroH2A1.1 alternative splicing is frequently perturbed in cancer15, and we find that impaired macroH2A1.1 splicing is predictive of increased sensitivity to TOP1 poisons in cancer cell lines, as well as improved survival outcome in ovarian cancer patients treated with TOP1 inhibitors (TOP1i). The gene discussed is MACROH2A1; the disease is ovarian cancer.